Large-scale manufacturing and characterization of CMV-CD19CAR T cells.

ABSTRACT:

Background

Adoptive transfer of CD19-specific chimeric antigen receptor (CD19CAR) T cells can induce dramatic disease regression in patients with B cell malignancies. CD19CAR T cell therapy may be limited by insufficient engraftment and persistence, resulting in tumor relapse. We previously demonstrated a proof of principle that cytomegalovirus (CMV)-specific T cells can be isolated and enriched prior to CD19CAR transduction to produce CMV-CD19CAR T cells, and that these CMV-CD19CAR T cells can be expanded in vivo through CMV vaccination, resulting in better tumor control in a murine model. Here we developed a clinical platform for generating CMV-CD19CAR T cells.

Methods

Peripheral blood mononuclear cells (PBMCs) collected from CMV-seropositive healthy donors were stimulated

SUBMITTER: Wang X 

PROVIDER: S-EPMC8762141 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature